CoronaryAtlas logo
CoronaryAtlas
Adiponectin
Pathway / Plaque inflammation

Adiponectin

ADIPOQprotein

Adiponectin suppresses plaque inflammation and endothelial dysfunction, exerting cardioprotection against atherothrombotic injury.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleAnti-inflammatory, antiatherogenic, cardioprotective; reduces oxidative stress and vascular inflammation.
Also acts inEndothelial activation/erosion, Systemic / off-pathway
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000181092

Type I vs Type II discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — confounder / Type-II
33
A — assay feasibility
68
E — evidence strength
25
T1DI (composite)
7
Specificity differential (R−C)-18.3
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuremag 1
6hypertensive emergencymag 1
7high-demand / peri-operative stressmag 1
Coverage: 4/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 7 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(18)